ProCE Banner Activity

ELM-2 Exploratory Analysis: Association Between ctDNA-Assessed Measurable Residual Disease Status and PFS With Odronextamab in R/R FL and DLBCL

Conference Coverage

Exploratory analysis of the ELM-2 study suggested that ctDNA-based MRD analysis and molecular characterization may be used to predict PFS outcomes in patients with R/R FL and DLBCL treated with odronextamab. 

Released: December 13, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.